Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis

Abstract

With the development of molecular pathology, many types of epidermal growth factor receptor (EGFR) mutations have been identified. The efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC) patients with different types of EGFR mutations, especially in patients with single rare mutations or complex mutations (co-occurrence of two or more different mutations), has not been fully understood. This study aimed to examine the efficacy of EGFR-TKIs in NSCLC patients with different types of EGFR mutations. Clinical data of 809 NSCLC patients who harbored different types of EGFR mutations and treated from January 2012 to October 2016 at Renmin Hospital and Zhongnan Hospital, Wuhan, were retrospectively reviewed. The clinical characteristics of these patients and the efficacy of EGFR-TKIs were analyzed. Among these patients, 377 patients had only the EGFR del-19 mutation, 362 patients the EGFR L858R mutation in exon 21, 33 patients single rare mutations and 37 patients complex mutations. Among these 809 patients, 239 patients were treated with EGFR-TKIs. In all the 239 patients, the disease control rate (DCR) was 93.7% with two patients (0.2%) achieving complete response (CR), the median progression free survival (PFS) was 13.0 months (95% confidence interval [CI], 11.6–14.4 months), and the median overall survival (OS) was 55.0 months (95% CI, 26.3–83.7 months). Subgroup analysis revealed that the DCR in patients harboring single rare or complex mutations of EGFR was significantly lower than in those with del-19 or L858R mutation (P<0.001). Patients with classic mutations (del-19 and/or L858R mutations) demonstrated longer PFS (P<0.001) and OS (P=0.017) than those with uncommon mutations (single rare and/or complex mutations). Furthermore, the patients with single rare mutations had shorter median OS than in those with other mutations. Multivariate Cox regression analysis identified that the type of EGFR mutations was an independent risk factor for PFS (hazard ratio [HR]=0.308, 95% CI, 0.191–0.494, P<0.001) and OS (HR=0.221, 95% CI, 0.101–0.480, P<0.001). The results suggest that the single rare or complex EGFR mutations confer inferior efficacy of EGFR-TKIs treatment to the classic mutations. The prognosis of the single rare EGFR mutations is depressing. EGFR-TKIs may be not a good choice for NSCLC patients with single rare mutations of EGFR. Further studies in these patients with uncommon mutations (especially for the patients with single rare mutations) are needed to determine a better precision treatment.

Keywords

non-small cell lung cancer / epidermal growth factor receptor / rare mutations / complex mutations / tyrosine kinase inhibitors

References

[1] SiegelRL, MillerKD, JemalA. Cancer statistics, 2016. CA Cancer J Clin, 2016, 66(1): 7-30 PMID: 26742998

[2] JemalA, BrayF, CenterMM, et al. . Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90 PMID: 21296855

[3] RoengvoraphojM, TsongalisGJ, DragnevKH, et al. . Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat Rev, 2013, 39(8): 839-850 PMID: 23768755

[4] ParumsDV. Current status of targeted therapy in non-small cell lung cancer. Drugs Today, 2014, 50(7): 503-525

[5] MitsudomiT, MoritaS, YatabeY, et al. . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128 PMID: 20022809

[6] ZhouC, WuYL, ChenG, et al. . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742 PMID: 21783417

[7] RosellR, CarcerenyE, GervaisR, et al. . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13(3): 239-246 PMID: 22285168

[8] SequistLV, YangJC, YamamotoN, et al. . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31(27): 3327-3334 PMID: 23816960

[9] WuYL, ZhouC, HuCP, et al. . Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15(2): 213-222 PMID: 24439929

[10] EttingerDS, WoodDE, AkerleyW, et al. . Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw, 2015, 13(5): 515-524 PMID: 25964637

[11] LevyBP, ChiodaMD, HerndonD, et al. . Molecular testing for treatment of metastatic non-small cell lung cancer: How to implement evidence-based recommendations. Oncologist, 2015, 20(10): 1175-1181 PMID: 26330460 PMCID: 4591939

[12] RosellR, MoranT, QueraltC, et al. . Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009, 361(10): 958-967 PMID: 19692684

[13] LeeHJ, KimYT, KangCH, et al. . Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology, 2013, 268(1): 254-264 PMID: 23468578

[14] D'ArcangeloM, D'InceccoA, CappuzzoF. Rare mutations in non-small-cell lung cancer. Future Oncol, 2013, 9(5): 699-711 PMID: 23647298

[15] WuJY, YuCJ, ChangYC, et al. . Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res, 2011, 17(11): 3812-3821 PMID: 21531810

[16] HataA, YoshiokaH, FujitaS, et al. . Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer. J Thorac Oncol, 2010, 5(10): 1524-1528 PMID: 20808254

[17] EisenhauerEA, TherasseP, BogaertsJ, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45(2): 228-247 PMID: 19097774

[18] HoriikeA, KimuraH, NishioK, et al. . Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest, 2007, 131(6): 1628-1634 PMID: 17565015

[19] JacobsonTA, LundahlJ, MellstedtH, et al. . Gene expression analysis using long-term preserved formalin-fixed and paraffin-embedded tissue of non-small cell lung cancer. Int J Oncol, 2011, 38(4): 1075-1081 PMID: 21305253

[20] ShiY, AuJS, ThongprasertS, et al. . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol, 2014, 9(2): 154-162 PMID: 24419411 PMCID: 4132036

[21] WeiZ, AnT, WangZ, et al. . Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors. Thorac Cancer, 2014, 5(2): 126-132 PMID: 26766989 PMCID: 4704323

[22] KuiperJL, HashemiSM, ThunnissenE, et al. . Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br J Cancer, 2016, 115(12): 1504-1512 PMID: 27875527 PMCID: 5155366

[23] KeamB, KimDW, ParkJH, et al. . Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. Int J Clin Oncol, 2014, 19(4): 594-600 PMID: 23912954

[24] ChenD, SongZ, ChengG. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco Targets Ther, 2016, 9: 4181-4186 PMID: 27468240 PMCID: 4944908

[25] KlughammerB, BruggerW, CappuzzoF, et al. . Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations. J Thorac Oncol, 2016, 11(4): 545-555 PMID: 26773740

[26] HirschFR, BunnP Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol, 2009, 10(5): 432-433 PMID: 19410185

[27] Beau-FallerM, PrimN, RuppertAM, et al. . Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol, 2014, 25(1): 126-131 PMID: 24285021

[28] KobayashiS, CanepaHM, BaileyAS, et al. . Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol, 2013, 8(1): 45-51 PMID: 23242437 PMCID: 3531043

[29] De PasT, ToffalorioF, ManzottiM, et al. . Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol, 2011, 6(11): 1895-1901 PMID: 21841502

[30] WuSG, ChangYL, HsuYC, et al. . Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist, 2008, 13(12): 1276-1284 PMID: 19060236

[31] ArrietaO, CardonaAF, CorralesL, et al. . The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer, 2015, 87(2): 169-175 PMID: 25558790

[32] ChiuCH, YangCT, ShihJY, et al. . Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol, 2015, 10(5): 793-799 PMID: 25668120

[33] BaekJH, SunJM, MinYJ, et al. . Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. Lung Cancer, 2015, 87(2): 148-154 PMID: 25498243

[34] IgawaS, RyugeS, IchinoeM, et al. . Impact of EGFR-tyrosine kinase inhibitors on postoperative recurrent non-small-cell lung cancer harboring EGFR mutations. Oncol Res Treat, 2017, 40(1-2): 7-13 PMID: 28118631

[35] WangJ, NongJ, JiaH, et al. . Efficacy and predictors of EGFR tyrosine kinase inhibitors in Chinese advanced lung adenocarcinoma: analyses of 253 cases from a single institute. Oncol Res, 2014, 21(5): 237-246 PMID: 24854100

[36] KimDW, LeeSH, LeeJS, et al. . A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer, 2011, 71(1): 65-69 PMID: 20430469

[37] KoyamaN, WatanabeY, IwaiY, et al. . Distinct benefit of overall survival between patients with non-small-cell lung cancer harboring EGFR exon 19 deletion and exon 21 L858R substitution. Chemotherapy, 2017, 62(3): 151-158 PMID: 28110331

[38] ChangHC, ChenYM, TsengCC, et al. . Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Tumour Biol, 2017, 39(3): 1010428317695939 PMID: 28351317

[39] MaemondoM, InoueA, KobayashiK, et al. . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388 PMID: 20573926

[40] KanchaRK, von BubnoffN, PeschelC, et al. . Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res, 2009, 15(2): 460-467 PMID: 19147750

[41] ChenYR, FuYN, LinCH, et al. . Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene, 2006, 25(8): 1205-1215 PMID: 16205628

[42] ImprotaG, PettinatoA, GieriS, et al. . Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. Oncol Lett, 2016, 11(1): 393-398 PMID: 26870223

[43] SchmidS, GautschiO, RothschildS, et al. . Clinical outcome of ALK-positive non-small cell lung cancer (NSCLC) patients with de novo EGFR or KRAS co-mutations receiving tyrosine kinase inhibitors (TKIs). J Thorac Oncol, 2017, 12(4): 681-688 PMID: 28007627

[44] SimonE, BickT, SarjiS, et al. . Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas. Oncotarget, 2017, 8(28): 45736-45749 PMID: 28501852 PMCID: 5542222